Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer.

ABSTRACT: PARP inhibitors have revolutionized ovarian cancer treatment, with benefits strongly linked to the presence of Homologous Recombination Deficiency (HRD). Although HRD testing was originally conducted on centralized platforms, there is growing demand for scalable, accessible, and robust solutions capable of supporting expanded clinical utilization. In the present study, a decentralized NGS-based assay was compared for its ability to effectively identify HRD positive patients when compared to the reference assay as well as other testing platforms. Eighty-two cases of ovarian cancer patients previously tested using the reference HRD assay (Myriad MyChoice® CDx assay) were evaluated by an NGS based HRD assay, the 1021-HRD assay (GenePlus), that provides genomic instability (GI) analysis along

SUBMITTER: Papadopoulou E 

PROVIDER: S-EPMC12718156 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature